Robert P Anderson

List of Publications by Year
in descending order

49 papers	3,581 citations	201674 27 h-index	214800 47 g-index
49 all docs	49 docs citations	49 times ranked	2821 citing authors

#	Article	IF	Citations
1	Plasma IL-2 and Symptoms Response after Acute Gluten Exposure in Subjects With Celiac Disease or Nonceliac Gluten Sensitivity. American Journal of Gastroenterology, 2022, 117, 319-326.	0.4	16
2	Emergence of an adaptive immune paradigm to explain celiac disease: a perspective on new evidence and implications for future interventions and diagnosis. Expert Review of Clinical Immunology, 2022, 18, 75-91.	3.0	5
3	Review article: Diagnosis of coeliac disease: a perspective on current and future approaches. Alimentary Pharmacology and Therapeutics, 2022, 56, .	3.7	6
4	The Gluten Gene: Unlocking the Understanding of Gluten Sensitivity and Intolerance. The Application of Clinical Genetics, 2021, Volume 14, 37-50.	3.0	21
5	A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease. Frontiers in Immunology, 2021, 12, 661622.	4.8	14
6	Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 875-884.	17.8	34
7	Editorial: Lessons on T-Cells and Immune-Targeting Therapeutics in Coeliac Disease. Frontiers in Immunology, 2021, 12, 756087.	4.8	0
8	Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease. Clinical and Experimental Immunology, 2021, 204, 321-334.	2.6	15
9	Editorial: towards an understanding of increased mortality in coeliac disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 654-655.	3.7	2
10	Cytokine release after gluten ingestion differentiates coeliac disease from selfâ€reported gluten sensitivity. United European Gastroenterology Journal, 2020, 8, 108-118.	3.8	26
11	T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease. Nature Structural and Molecular Biology, 2020, 27, 49-61.	8.2	91
12	Update 2020: nomenclature and listing of celiac diseaseâ€“relevant gluten epitopes recognized by CD4+ T cells. Immunogenetics, 2020, 72, 85-88.	2.4	125
13	Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 244-252.	3.7	27
14	Innate and adaptive immunity in celiac disease. Current Opinion in Gastroenterology, 2020, 36, 470-478.	2.3	3
15	Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. BMC Medicine, 2020, 18, 362.	5.5	22
16	Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on glutenâ€free diet. GastroHep, 2020, 2, 22-30.	0.6	43
17	Circulating glutenâ€specific, but not CMVâ€specific, CD39 + regulatory T cells have an oligoclonal TCR repertoire. Clinical and Translational Immunology, 2020, 9, e1096.	3.8	7
18	Editorial: inaccuracies in attribution of symptoms due to glutenâ€”not just in those with selfâ€reported noncoeliac gluten sensitivity. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 403-404.	3.7	1

#	Article	IF	Citations
19	Effects of In Vivo Gluten Challenge on PBMC Gene Expression Profiles in Diet Treated Celiac Disease. Frontiers in Immunology, 2020, 11, 594243.	4.8	4
20	Randomised clinical trial: a placeboâ€controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 547-555.	3.7	35
21	Elevated serum interleukinâ€2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 901-910.	3.7	51
22	Editorial: a nonâ€dietary treatment for coeliac diseaseâ€"two steps forward, one step back? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 956-957.	3.7	5
23	Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Science Advances, 2019, 5, eaaw7756.	10.3	84
24	Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease. Clinical and Experimental Immunology, 2019, 199, 68-78.	2.6	36
25	Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. The Lancet Gastroenterology and Hepatology, 2017, 2, 479-493.	8.1	113
26	Circulating gluten-specific FOXP3 + CD39 + regulatory T cells have impaired suppressive function in patients with celiac disease. Journal of Allergy and Clinical Immunology, 2017, 140, 1592-1603.e8.	2.9	63
27	Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. EBioMedicine, 2017, 26, 78-90.	6.1	51
28	Deep sequencing of blood and gut T-cell receptor Î²-chains reveals gluten-induced immune signatures in celiac disease. Scientific Reports, 2017, 7, 17977.	3.3	31
29	Sa1395 Nexvax2Â®, a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People With Celiac Disease (CeD). Gastroenterology, 2016, 150, S304.	1.3	2
30	Reply. Gastroenterology, 2016, 150, 779-780.	1.3	0
31	Consistency in Polyclonal T-cell Responses to Gluten Between Children and Adults With Celiac Disease. Gastroenterology, 2015, 149, 1541-1552.e2.	1.3	46
32	Ingestion of oats and barley in patients with celiac disease mobilizesÂcross-reactive T cells activated by avenin peptides andÂimmuno-dominant hordein peptides. Journal of Autoimmunity, 2015, 56, 56-65.	6.5	62
33	Ex-vivo whole blood secretion of interferon (IFN)-Î³ and IFN-Î³-inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-Î³ enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2Â·5+-associated coeliac disease. Clinical and Experimental Immunology, 2014, 175, 305-315.	2.6	50
34	T-cell receptor recognition of HLA-DQ2â€"gliadin complexes associated with celiac disease. Nature Structural and Molecular Biology, 2014, 21, 480-488.	8.2	177
35	Vaccine against autoimmune disease: antigen-specific immunotherapy. Current Opinion in Immunology, 2013, 25, 410-417.	5.5	65
36	A novel serogenetic approach determines the community prevalence of celiac disease and informs improved diagnostic pathways. BMC Medicine, 2013, 11, 188.	5.5	88

#	Article	IF	Citations
37	Biased T Cell Receptor Usage Directed against Human Leukocyte Antigen DQ8-Restricted Gliadin Peptides Is Associated with Celiac Disease. Immunity, 2012, 37, 611-621.	14.3	121
38	Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics, 2012, 64, 455-460.	2.4	442
39	A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2Â® in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet. Gastroenterology, 2011, 140, S-437-S-438.	1.3	31
40	Suppression of Inflammatory Immune Responses in Celiac Disease by Experimental Hookworm Infection. PLoS ONE, 2011, 6, e24092.	2.5	105
41	The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clinical Immunology, 2010, 134, 289-295.	3.2	125
42	Comprehensive, Quantitative Mapping of T Cell Epitopes in Gluten in Celiac Disease. Science Translational Medicine, 2010, 2, 41ra51.	12.4	393
43	Resistance to Celiac Disease in Humanized HLA-DR3-DQ2-Transgenic Mice Expressing Specific Anti-Gliadin CD4+ T Cells. Journal of Immunology, 2009, 182, 7440-7450.	0.8	85
44	A Structural and Immunological Basis for the Role of Human Leukocyte Antigen DQ8 in Celiac Disease. Immunity, 2007, 27, 23-34.	14.3	157
45	A systematic approach for comprehensive T-cell epitope discovery using peptide libraries. Bioinformatics, 2005, 21, i29-i37.	4.1	17
46	T cells in peripheral blood after gluten challenge in coeliac disease. Gut, 2005, 54, 1217-1223.	12.1	110
47	In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nature Medicine, 2000, 6, 337-342.	30.7	521
48	Protective Role of the Epithelium of the Small Intestine and Colon. Inflammatory Bowel Diseases, 1996, 2, 279-302.	1.9	28
49	Protective role of the epithelium of the small intestine and colon. Inflammatory Bowel Diseases, 1996, 2, 279-302.	1.9	25